Skip to main content

Fyarro FDA Approval History

Last updated by Judith Stewart, BPharm on Nov 24, 2021.

FDA Approved: Yes (First approved November 22, 2021)
Brand name: Fyarro
Generic name: sirolimus protein-bound
Dosage form: Lyophilized Powder for Injectable Suspension
Company: Aadi Bioscience, Inc.
Treatment for: Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Fyarro (sirolimus protein-bound particles) is an inhibitor of mechanistic target of rapamycin kinase (mTOR) for the treatment of malignant perivascular epithelioid cell tumor (PEComa).

Development timeline for Fyarro

Nov 23, 2021Approval FDA Approves Fyarro (sirolimus protein-bound particles) for the Treatment of Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.